COVID-19 vaccines: research and development
The European Medicines Agency (EMA) is interacting with developers of potential COVID-19 vaccines to enable its distribution in the European Union (EU) as soon as possible.
EMA is providing guidance to assist developers of potential COVID-19 vaccines to prepare for eventual applications for marketing authorisation.
The outcome of any consultation or advice from EMA is not binding on developers.
|Product||Developer||Development stage at time of guidance|
|Ad26.COV2.S||Janssen-Cilag International N.V.||Non-clinical phase|
|Ad5-nCoV vaccine||Cansino Biotech||Clinical phase|
|Adjuvanted whole virion inactivated vaccine||Sinovac Biotech Ltd||Non-clinical phase|
|Coronavirus-like particle (COVLP)||Medicago||Non-clinical phase|
|CVnCoV, CV07050101 vaccine||Curevac||Non-clinical phase|
|Herpes simplex virus vector tetravalent SARS-CoV-2 vaccine||Krystal Bio||Non-clinical phase|
|LNP-saRNA CoVid19 vaccine||VacEquity Global Health/Imperial College London||Clinical phase|
|LUNAR-COV19 mRNA vaccine||Arcturus Therapeutics||Clinical phase|
|mRNA SARS-CoV-2 vaccine||Biontech||Non-clinical phase|
|mRNA-1273 SARS-CoV-2 vaccine||Moderna||Non-clinical phase|
|MV-SARS-CoV-2 vaccine||Themis Bioscience GmbH/MSD||Non-clinical phase|
|NVX-CoV-2 rS||Novavax||Non-clinical phase|
|Protein nanoparticle vaccine||Emergex Vaccines Holding Ltd||Non-clinical phase|
|rVSVΔG-SARS-CoV-2 live attenuated||MSD/IAVI||Non-clinical phase|
|SARS-CoV-2 DNA vaccine||Inovio||Non-clinical phase|
|SARS-Cov-2 vaccine||Queensland University/Seqirus||Non-clinical phase|
|SARS-CoV-2 vaccine recombinant, adjuvanted||Sanofi Pasteur||Non-clinical phase|
|S-trimer subunit vaccine||Clover Biopharma||Clinical phase|
|Subunit vaccine adjuvanted||Medigen||Non-clinical phase|
|VLA 2001 vaccine||Valneva||Non-clinical phase|
|Protein vaccine adjuvanted||Kentucky Bioprocessing, Inc||Non-clinical phase|
|DNA Plasmid vaccine||Takis S.r.l., Rottapham Biotech||Non-clinical phase|
|Gam-COVID-Vac||The Gamaleya National Centre of Epidemiology and microbiology||Clinical Phase|
|mRNA vaccine||Valneva||Non-clinical phase|
|MRT550 mRNA vaccine||Sanofi||Non-clinical phase|
|UB-612||Vaxxinity (Covaxx) / UBI (United Biomedical, Inc.)||Clinical phase|
|MVA-SARS-2-S and MVA-SARS-2-ST||IDT-Biologika / German Center for Infection Research (DZIF)||Clinical phase|
This information should not be read as an endorsement of any medicine.
Users can find information on:
- phase II to phase IV adult clinical trials for COVID-19 vaccines where the investigator sites are in the EEA;
- any clinical trials in children with investigator sites in the EU and any trials that form part of a paediatric investigation plan, including those where the investigator sites are outside the EU.
Phase I clinical trials conducted solely in adults are not made publicly available in the EU CTR.
For more information on the EU CTR and how clinical trials are authorised and overseen in the EEA, see: